One dose of PD-1 blockade predicts melanoma outcome

Neoadjuvant treatment with pembrolizumab was effective in 30% of patients

The response to a single dose of neoadjuvant PD-1 (programmed cell death protein 1) blockade predicts clinical outcomes in patients with stage III or IV resectable melanoma, researchers report.